SCHEDULE: Ayrton Capital Divests Entire Stake in Co-Diagnostics

Ayrton Capital LLC and its affiliates have reported a complete divestment of their beneficial ownership in Co-Diagnostics, Inc., now holding 0% of the common stock.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing indicates that as of December 31, 2025, the Reporting Persons beneficially own 0 shares of Co-Diagnostics, Inc. common stock, representing 0% of the class.
• This marks a complete divestment from their previous reportable stake in the company.
• The percentage of class is based on 60,892,582 shares of common stock outstanding as of November 11, 2025, as reported in the Issuer's Form 10-Q filed on November 13, 2025.
• Ayrton Capital LLC serves as the investment manager for Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri is the managing member of Ayrton Capital LLC.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development. While a 13G filing is purely informational, the complete divestment by a significant institutional holder can imply a loss of confidence or a strategic shift away from the issuer, which may concern other investors.

Negatives

• The complete divestment of shares by Ayrton Capital LLC and its affiliates could be perceived negatively by the market, signaling a lack of confidence from a previous significant investor.

Risks

• The divestment by a significant institutional investor may lead to increased selling pressure on the stock if other investors interpret this as a negative signal.
• A reduction in institutional ownership can sometimes reduce stock liquidity and increase volatility.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Co-Diagnostics, Inc. or the Reporting Persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that a Schedule 13G amendment reporting 0% ownership indicates a complete exit by a previously reportable passive investor. While not uncommon, such a divestment by an institutional fund like Alto Opportunity Master Fund, managed by Ayrton Capital, can sometimes be interpreted by the market as a signal regarding the company's prospects or the fund's portfolio strategy.

Comparison to Industry Standards

• The divestment of an entire stake by an institutional investor is a standard event in portfolio management, often driven by rebalancing, strategic shifts, or changes in investment thesis.
• Without specific reasons provided in the filing, it is difficult to compare this action to similar divestments by funds from other companies in the diagnostics or biotechnology sector, such as those seen with ARK Invest's adjustments in biotech holdings or BlackRock's reallocations in various industries.

Stakeholder Impact

• Shareholders may react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.
• The divestment could lead to a shift in the company's shareholder base, potentially impacting future voting dynamics if other large investors emerge or reduce their holdings.

Key Dates

Keywords

Co-Diagnostics, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, SEC Filing